MedPath

A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s lymphoma - R-CHOP 14 vs. 21

Phase 1
Conditions
ewly diagnosed diffuse large B cell non-Hodgkin's lymphoma
Registration Number
EUCTR2004-002197-34-GB
Lead Sponsor
niversity College London
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
1080
Inclusion Criteria

a) Age ? 18 years.
b) Histologically proven diffuse large B cell non-Hodgkin’s lymphoma (DLBCL) according to the current World Health Organisation classification14 including all morphological variants. The B cell nature of the proliferation must be verified by the positivity with an anti-CD20 antibody. All histology will be reviewed by a central Lymphoma Trials Office pathology panel.
c) Bulky stage IA (defined as lymph node or lymph node mass greater than 10cm in diameter), stage II, stage III and IV.
d) No previous chemotherapy, radiotherapy or other investigational drug for this indication.
e) Written, informed consent.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

a) T-cell lymphoma or transformed follicular lymphoma.
b) Previous history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed who have a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.
c) Any medical condition compromising ability to tolerate chemotherapy

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To evaluate the improvement in overall survival of rituximab combined with CHOP given every 14 days (R-CHOP 14) in comparison to rituximab with CHOP given every 21 days (R-CHOP 21);Secondary Objective: To assess failure free survival, toxicity up to and including 30 days from date of last treatment and complete response rates;<br> Primary end point(s): Overall survival<br><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath